MannKind | MNKD - Ebit


MannKind reported $-41.05M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Adma Biologics USD 49.19M 7.26M Sep/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Eli Lilly USD 8.99B 1.57B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
MacroGenics USD 20.16M 55.51M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD -134.02M 49.55M Sep/2024
Novo Nordisk DKK 5.18B 37.04B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Xencor USD -47.52M 24.69M Sep/2025